Biagio Ricciuti

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

Biagio Ricciuti
Dec 8, 2024, 06:05 | Insight
Alessandro Di Federico: Lung adenocarcinomas with Mucinos Histology
Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a…
Nov 27, 2024, 15:46 | Blog
Biagio Ricciuti: Discussing immunotherapy and targeted therapy for KRAS + NSCLC
Biagio Ricciuti, thoracic oncologist at the Dana-Farber Cancer Institute, shared a post on X by…
Nov 25, 2024, 17:53 | Insight
Safety of Lorlatinib in ALK positive NSCLC
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber and Harvard Medical School, shared a recent article…
Nov 25, 2024, 10:10 | Insight
Highlights from Masters in Thoracic Oncology Summit (MaTOS) 2024
2024 Masters in Thoracic Oncology Summit took place from November 21st to the 24th at…
Nov 24, 2024, 15:53 | Blog
Xiuning Le: Wrapping up MaTOS24 in beautiful Lake Tahoe
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared…
Oct 29, 2024, 13:05 | Insight
Paolo Tarantino: My 100th scientific publication
Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "It turns out…
Oct 16, 2024, 17:00 | Insight
Biagio Ricciuti: 5-year update from the NADIM trial
Biagio Ricciuti shared a post on X about a recent paper by Mariano Provencio et…
Oct 9, 2024, 16:38 | Blog
Stephen V Liu: Case report of MET mediating resistance to entrectinib in ROS1 NSCLC
Stephen V Liu shared a post on X: "Case report of MET mediating resistance to entrectinib…
Oct 5, 2024, 16:04 | Societies
Highlights From ILCS24
The 6th International Lung Cancer Summit was held in Lausanne, Switzerland on October 4, 2024,…
Oct 5, 2024, 12:11 | Blog
Biagio Ricciuti: Stephen Liu on the evolving treatment landscape for SCLC
Biagio Ricciuti shared a post on X: "Comprehensive overview of the evolving treatment landscape for…
Sep 13, 2024, 14:12 | Blog
Xiuning Le: BAY88 in pre-treated HER2-mut NSCLC
Xiuning Le shared  a post by Biagio Ricciuti, on X, adding: "BAY88 in pre-treated HER2-mut…
Sep 11, 2024, 01:59 | Societies
38 Posts Not to Miss From WCLC24 Day 3!
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Sep 6, 2024, 13:28 | Insight
Biagio Ricciuti: How adaptive mechanisms and increased GTP loading confer resistance to KRAS G12C OFF
Biagio Ricciuti shared on X: “Our in Nature Communications our collaborative effort showing how adaptive mechanisms…
Aug 27, 2024, 23:18 | Insight
Explore the current therapeutic landscape for Lung Cancer with Biagio Ricciuti at the upcoming ILCS24
International Lung Cancer Summit (ILCS) shared on X: “What is the current therapeutic landscape for Lung…
Aug 18, 2024, 06:12 | Blog
Biagio Ricciuti: KEAPness signature outperforms deleterious KEAP1 mutations in predicting ICI efficacy in NSCLC
Biagio Ricciuti shared on X: "Sharing our latest effort out in Clinical Cancer Research! This multicenter…
Aug 16, 2024, 14:13 | Insight
OS rates for IMpower133 and IMbrella A extension study in SCLC
Biagio Ricciuti shared a paper by Martin Reck et al. on X, adding: “Five-year survival…
Aug 12, 2024, 06:16 | Insight
Biagio Ricciuti: In vivo vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Biagio Ricciuti shared a post on LinkedIn about his recent paper, commenting: “Our collaborative effort…
Aug 12, 2024, 02:37 | Blog
Biagio Ricciuti: Vulnerabilities to GPX4 and HDAC inhibitors in BRAF V600E lung adenocarcinoma
Biagio Ricciuti posted on X about recent paper by Marie-Julie Nokin et al., titled "In…
Aug 9, 2024, 12:23 | Blog
The 6th International Lung Cancer Summit
The 6th International Lung Cancer Summit is a hybrid conference that will be held at…
Aug 7, 2024, 20:03 | Insight
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion summarized by Biagio Ricciuti
Biagio Ricciuti shared a post on X: "Recurrence of Non–Small Cell Lung Cancer With Visceral…
Aug 6, 2024, 06:07 | Insight
Primary analysis of the phase 2 INSIGHT 2 study of tepotinib combined with osimertinib
Lungevity Foundation shared a recent article by Yi-Long Wu, commenting: "What's after osimertinib for pts…
Jul 31, 2024, 09:17 | Blog
New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC
IASLC shared on X: "In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed…
Jul 30, 2024, 01:45 | Insight
TKIs with vs without upfront SRS for EGFR+ and ALK+ NSCLC and brain metastasis
Biagio Ricciuti shared on X about a recent paper by Luke Pike et al. titled…
Jul 21, 2024, 20:02 | Blog
Biagio Ricciuti: Join us in Lausanne for the 2024 International Lung Cancer Summit
Biagio Ricciuti shared a post on X by the International Lung Cancer Summit, adding: "Join…
Jul 14, 2024, 06:26 | Insight
Daniele Marinelli: NRF2-driven transcription in NSCLC
Daniele Marinelli, PhD student at the Sapienza University of Rome, shared a post on X…
Jul 12, 2024, 23:29 | Insight
Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC
Biagio Ricciuti shared on X: "Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC…
Jul 10, 2024, 02:17 | Blog
Biagio Ricciuti: Resistance mechanisms in insertion-mutant NSCLC
Biagio Ricciuti shared on X: "Resistance mechanisms to EGFR TKIs in EGFR ex 20 insertion-mutant NSCLC:…
Jul 9, 2024, 07:10 | Insight
10 Papers Suggested By Wafik S. El-Deiry on July 9
Wafik S. El-Deiry, Director of the Legorreta Cancer Center of Brown University and Associate Dean for…
Jul 1, 2024, 02:31 | Blog
Biagio Ricciuti receives a 2024 IASLC YIA to develop new therapies for KRAS amplified NSCLC
Biagio Ricciuti shared a post by Dana-Farber News, on X: "Thrilled to receive a 2024…
Jun 28, 2024, 04:59 | Blog
Mihaela Aldea received a 2024 IASLC YIA
Mihaela Aldea, Medical Oncologist at the Gustave Roussy, shared a post on X: "Honored to…
Jun 27, 2024, 20:12 | Blog
Dana-Farber News - Biagio Ricciuti receives IASLC 2024 Young Investigator Grant
Dana-Farber News shared on X: "Congratulations to Biagio Ricciuti, who is a recipient of the IASLC…
Jun 21, 2024, 04:15 | Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 20, 2024, 12:07 | Insight
Research into why some respond to TKIs better than others - Oncogene Cancer Research
Oncogene Cancer Research recently shared a post on X: "Worth reading this deep dive into…
May 31, 2024, 02:35 | Blog
Biagio Ricciuti: Great conversation on the role of ICI in patients with NSCLC and driver mutations
Biagio Ricciuti shared a post by Narjust Florez on X, adding:   , "I had a…
May 29, 2024, 09:25 | Insight
Biagio Ricciuti: The association of automatically extracted body composition metrics with IO efficacy in mNSCLC
Biagio Ricciuti, recently posted on X: "Out in JAMA Oncology! Our effort to determine the…
May 12, 2024, 13:30 | Blog
Biagio Ricciuti: Insightful discussions at Rome Lung 24
Biagio Ricciuti shared a post by Stephen Liu on X and added: "Had a great…
May 11, 2024, 12:13 | Insight
Biagio Ricciuti: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: "Comprehensive mutational scanning of EGFR…
Apr 26, 2024, 10:00 | Insight
Biagio Ricciuti: Our work on long-term outcomes to PD-1 monotherapy by increasing PD-L1 levels in NSCLC is out in JTO and JTO CRR
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''Our work on long-term…
Apr 9, 2024, 13:33 | Blog
Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''If you are at…
Apr 8, 2024, 23:10 | Blog
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "Our collaborative effort…
Apr 8, 2024, 14:35 | Insight
Biagio Ricciuti: Our collaborative effort to characterize MET kinase domain mutations as novel and targetable alterations in NSCLC and other cancer types
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, posted on X: "Our collaborative effort to…
Apr 7, 2024, 23:28 | Insight
Biagio Ricciuti: MET kinase domain mutations as novel & targetable alterations in NSCLC and other cancer types
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X: "Our collaborative effort to…
Jan 18, 2024, 15:55 | Blog
Biagio Ricciuti: Mechanisms of acquired resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on LinkedIn: “Now out in the…
All: 43 Posts: 1 - 100
Special Coverage